Nature Communications (Oct 2020)
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
- Melanie Werner-Klein,
- Ana Grujovic,
- Christoph Irlbeck,
- Milan Obradović,
- Martin Hoffmann,
- Huiqin Koerkel-Qu,
- Xin Lu,
- Steffi Treitschke,
- Cäcilia Köstler,
- Catherine Botteron,
- Kathrin Weidele,
- Christian Werno,
- Bernhard Polzer,
- Stefan Kirsch,
- Miodrag Gužvić,
- Jens Warfsmann,
- Kamran Honarnejad,
- Zbigniew Czyz,
- Giancarlo Feliciello,
- Isabell Blochberger,
- Sandra Grunewald,
- Elisabeth Schneider,
- Gundula Haunschild,
- Nina Patwary,
- Severin Guetter,
- Sandra Huber,
- Brigitte Rack,
- Nadia Harbeck,
- Stefan Buchholz,
- Petra Rümmele,
- Norbert Heine,
- Stefan Rose-John,
- Christoph A. Klein
Affiliations
- Melanie Werner-Klein
- Experimental Medicine and Therapy Research, University of Regensburg
- Ana Grujovic
- Experimental Medicine and Therapy Research, University of Regensburg
- Christoph Irlbeck
- Experimental Medicine and Therapy Research, University of Regensburg
- Milan Obradović
- Experimental Medicine and Therapy Research, University of Regensburg
- Martin Hoffmann
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Huiqin Koerkel-Qu
- Experimental Medicine and Therapy Research, University of Regensburg
- Xin Lu
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Steffi Treitschke
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Cäcilia Köstler
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Catherine Botteron
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Kathrin Weidele
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Christian Werno
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Bernhard Polzer
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Stefan Kirsch
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Miodrag Gužvić
- Experimental Medicine and Therapy Research, University of Regensburg
- Jens Warfsmann
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Kamran Honarnejad
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Zbigniew Czyz
- Experimental Medicine and Therapy Research, University of Regensburg
- Giancarlo Feliciello
- Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine
- Isabell Blochberger
- Experimental Medicine and Therapy Research, University of Regensburg
- Sandra Grunewald
- Experimental Medicine and Therapy Research, University of Regensburg
- Elisabeth Schneider
- Experimental Medicine and Therapy Research, University of Regensburg
- Gundula Haunschild
- Experimental Medicine and Therapy Research, University of Regensburg
- Nina Patwary
- Experimental Medicine and Therapy Research, University of Regensburg
- Severin Guetter
- Experimental Medicine and Therapy Research, University of Regensburg
- Sandra Huber
- Experimental Medicine and Therapy Research, University of Regensburg
- Brigitte Rack
- Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital
- Nadia Harbeck
- Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital
- Stefan Buchholz
- Clinic of Gynecology and Obstetrics, University Medical Center Regensburg
- Petra Rümmele
- Department of Pathology, University of Regensburg
- Norbert Heine
- University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery, University of Regensburg
- Stefan Rose-John
- Institute of Biochemistry, Christian-Albrechts-Universität Kiel
- Christoph A. Klein
- Experimental Medicine and Therapy Research, University of Regensburg
- DOI
- https://doi.org/10.1038/s41467-020-18701-4
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 18
Abstract
Metastatic dissemination in breast cancer patients occurs early in malignant transformation, raising questions about how disseminated cancer cells (DCC) progress at distant sites. Here, the authors show that DCCs in bone marrow are activated via IL6-trans-signaling and thereby acquire stemness traits relevant for metastasis formation.
